Cancer Drug Responses Fayetteville NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Christina Lee Wells, MD
(910) 484-4615
1133 Offshore Dr
Fayetteville, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Va Sch Of Med, Charlottesville Va 22908
Graduation Year: 1992

Data Provided by:
Herman Allen Godwin, MD
(919) 323-1152
1813 Lakeshore Dr
Fayetteville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Bowman Gray Sch Of Med Of Wake Forest Univ, Winston-Salem Nc 27157
Graduation Year: 1963

Data Provided by:
Shirish Devasthali, MD
(910) 483-8586
PO Box 53095
Fayetteville, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Languages
Hindi, Other, Russian
Education
Medical School: First Moscow Sechenov Med Inst, Moscow, Russia
Graduation Year: 1980
Hospital
Hospital: Cape Fear Valley Med Center, Fayetteville, Nc
Group Practice: Blood & Cancer Clinic

Data Provided by:
Mark Ketheeswaran
(910) 485-7003
1209 Cape Ct
Fayetteville, NC
Specialty
Hematology / Oncology

Data Provided by:
Kamal Manubhai Bakri
(910) 609-6910
1638 Owen Dr
Fayetteville, NC
Specialty
Internal Medicine, Medical Oncology

Data Provided by:
Tariq Nazir, MD
(910) 483-8586
PO Box 53095
Fayetteville, NC
Specialties
Internal Medicine, Hematology-Oncology
Gender
Male
Education
Medical School: Sind Med Coll, Univ Of Karachi, Karachi,
Graduation Year: 1990

Data Provided by:
Sajjad A Malick, MD
(910) 609-6910
PO Box 42935
Fayetteville, NC
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Dow Med Coll, Univ Of Karachi, Karachi, Pakistan
Graduation Year: 1988
Hospital
Hospital: Cape Fear Valley Med Center, Fayetteville, Nc; Betsy Johnson Mem Hosp, Dunn, Nc
Group Practice: Hematology Oncology Assoc

Data Provided by:
John Hugh Bryan, MD
(910) 609-6690
PO Box 41208
Fayetteville, NC
Specialties
Oncology (Cancer), Radiation Oncology, Pediatrics
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1969
Hospital
Hospital: Cape Fear Valley Med Center, Fayetteville, Nc; Southeastern Reg Med Ctr, Lumberton, Nc
Group Practice: South East Radiation Oncology

Data Provided by:
Surajit Chaudhuri, MD
(910) 483-8361
1205 Cape Ct Ste B
Fayetteville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Nrs Med Coll, Univ Of Calcutta, Calcutta, West Bengal, India
Graduation Year: 1982

Data Provided by:
Surajit Chaudhuri
(910) 483-8361
1205 Cape Ct
Fayetteville, NC
Specialty
Hematology / Oncology

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com